Skip to main content
SpringerLink
Log in

Chronic myelogenous leukemia

Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020. https://doi.org/10.1038/s41375-019-0700-9.

  2. Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016;3:e581–91.

    Article  Google Scholar 

  3. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112:3965–73.

    Article  CAS  Google Scholar 

  4. Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, et al. Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. Blood Adv. 2019;3:312–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

AEE would like to thank his mentor retired Prof. Teoman Soysal for his continuous support and guidance and he wishes him a long, happy, and healthy retirement.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

    Ahmet Emre Eşkazan

Authors
  1. Ahmet Emre Eşkazan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Emre Eşkazan.

Ethics declarations

Conflict of interest

AEE has received advisory board honorarium from Novartis, and he also received speaker bureau honoraria from Novartis, Bristol-Myers Squibb, and Pfizer outside the present study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eşkazan, A.E. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. Leukemia 34, 3426–3427 (2020). https://doi.org/10.1038/s41375-020-0796-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0796-y

  • Springer Nature Limited

Search

Navigation